F. Cabanillas

发表

Mantle cell lymphoma: a lymphoproliferative disorder associated with aberrant function of the cell cycle.

J. Garcia-conde, F. Cabanillas, 1996, Leukemia.

Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma.

L. Gordon, M. Czuczman, F. Cabanillas, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs.

James Allison, Stephen Forman, Massimo Cristofanilli, 2015, Mayo Clinic proceedings.

Dose-response analysis for radiotherapy delivered to patients with intermediate-grade and large-cell immunoblastic lymphomas that have completely responded to CHOP-based induction chemotherapy.

S. Tucker, J. Cox, F. Cabanillas, 2001, International journal of radiation oncology, biology, physics.

Liposomal vincristine in relapsed non-Hodgkin's lymphomas: early results of an ongoing phase II trial.

H. Kantarjian, P. Mclaughlin, F. Cabanillas, 2000, Annals of oncology : official journal of the European Society for Medical Oncology.

Human interferon alpha in malignant lymphoma and Hodgkin's disease. Results of the american cancer society trial

T. Merigan, S. Horning, F. Cabanillas, 1985, Cancer.

Chromosome X numerical abnormalities in patients with non-Hodgkin's lymphoma. A study of 59 patients using fluorescence in situ hybridization.

M. Andreeff, F. Cabanillas, A. Younes, 1995, Cancer genetics and cytogenetics.

High incidence of monosomy 18 in lymphoid malignancies that have bone marrow and peripheral blood involvement.

M. Andreeff, F. Cabanillas, A. Younes, 1994, Cancer genetics and cytogenetics.

Polysomy of chromosome 12 in 60 patients with non‐hodgkin's lymphoma assessed by fluorescence in situ hybridization: Differences between follicular and diffuse large cell lymphoma

Maria A. Rodriguez, M. Andreeff, F. Cabanillas, 1994, Genes, chromosomes & cancer.

Fludarabine, mitoxantrone, dexamethasone (FND) compared with an alternating triple therapy (ATT) regimen in patients with stage IV indolent lymphoma.

Terry L. Smith, Maria A. Rodriguez, P. Mclaughlin, 2002, Blood.

Long term results of a phase 2 study of vincristine sulfate liposome injection (Marqibo®) substituted for non‐liposomal vincristine in cyclophosphamide, doxorubicin, vincristine, prednisone with or without rituximab for patients with untreated aggressive non‐Hodgkin lymphomas

P. Mclaughlin, F. Cabanillas, L. Medeiros, 2013, British journal of haematology.

Hodgkin's Disease in Patients Infected with Human Immunodeficiency Virus: Frequency, Presentation and Clinical Outcome

P. Mclaughlin, F. Cabanillas, F. Cabanillas, 2001, Leukemia & lymphoma.

Recovery of spermatogenesis after treatment for Hodgkin's disease: limiting dose of MOPP chemotherapy.

W. Velasquez, L. Fuller, P. Mclaughlin, 1984, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

T-cell-rich B large-cell lymphoma simulating lymphocyte-rich Hodgkin's disease.

F. Cabanillas, N. Ordóñez, José Raúl Rodríguez Rodríguez, 1996, The American journal of surgical pathology.

Retinoid-mediated inhibition of cell growth with stimulation of apoptosis in aggressive B-cell lymphomas.

F. Cabanillas, K. Mehta, G. Lopez-Berestein, 1997, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

Immunosuppression and infectious complications in patients with stage IV indolent lymphoma treated with a fludarabine, mitoxantrone, and dexamethasone regimen

Terry L. Smith, Maria A. Rodriguez, P. Mclaughlin, 2005, Cancer.

Cyclosporin plus doxorubicin, vincristine and etoposide in the treatment of refractory non-Hodgkin's lymphoma: a phase II study.

D. Moore, F. Cabanillas, A. Sarris, 1995, Clinical oncology (Royal College of Radiologists (Great Britain)).

Therapeutic concepts in mantle cell lymphoma

F. Cabanillas, S. Fernández de Mattos, A. Obrador-Hevia, 2010, European journal of haematology.

Prospective trial of targeted radioimmunotherapy with Y-90 ibritumomab tiuxetan (Zevalin) for front-line treatment of early-stage extranodal indolent ocular adnexal lymphoma.

B. Esmaeli, P. Mclaughlin, F. Cabanillas, 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

A comparison of imipenem to ceftazidime with or without amikacin as empiric therapy in febrile neutropenic patients.

E. Anaissie, L. Elting, F. Cabanillas, 1992, Archives of internal medicine.

Subdiaphragmatic stage I & II Hodgkin's disease: long-term follow-up and prognostic factors.

Z. Liao, S. Tucker, L. Fuller, 1998, International journal of radiation oncology, biology, physics.

Long-term outcome of treatment for Ann Arbor stage 1 Hodgkin's disease: patterns of failure, late toxicity and second malignancies.

L. Fuller, J. Cox, B. Brown, 1997, International journal of radiation oncology, biology, physics.

UFT: mechanism of drug action.

F. Cabanillas, 2000 .

The role of topoisomerase-I inhibitors in the treatment of non-Hodgkin's lymphoma.

F. Cabanillas, 1999, Seminars in hematology.

Nonablative allogeneic hematopoietic transplantation as adoptive immunotherapy for indolent lymphoma: low incidence of toxicity, acute graft-versus-host disease, and treatment-related mortality.

P. Mclaughlin, F. Cabanillas, F. Cabanillas, 2001, Blood.

Allogeneic hematopoietic transplantation for indolent lymphomas: improved outcome with non-myeloablative versus high dose chemotherapy (HDCT) regimens

N. Ueno, F. Cabanillas, A. Younes, 2000 .

Non-Hodgkin's lymphoma. Clinical practice guidelines in oncology.

M. Caligiuri, R. Advani, J. Vose, 2006, Journal of the National Comprehensive Cancer Network : JNCCN.

Stages I-III follicular lymphoma: role of CT of the abdomen and pelvis in follow-up studies.

J. Cox, F. Cabanillas, C. Ha, 1999, Radiology.

Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma.

Michael L. Wang, P. Mclaughlin, F. Cabanillas, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Chemoimmunotherapy of advanced non Hodgkin's lymphoma (NHL) with CHOP Bleo + levamisole

E. Hersh, F. Cabanillas, V. Rodriguez, 1977 .

Curability of advanced indolent or low-grade follicular lymphomas: time for a new paradigm?

F. Cabanillas, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Rituximab in DLBCL: 6 years on.

F. Cabanillas, 2011, The Lancet. Oncology.

malignant lymphoma Combination chemotherapy ("CHOP-Bleo") in advanced (non-Hodgkin)

F. Cabanillas, E. Freireich, M. Valdivieso, 2011 .

The role of mitoxantrone in the treatment of indolent lymphomas.

P. Zinzani, F. Cabanillas, F. Hagemeister, 2005, The oncologist.

Combination chemotherapy ("CHOP-Bleo") in advanced (non-Hodgkin) malignant lymphoma.

F. Cabanillas, E. Freireich, G. Bodey, 1977, Blood.

Apoptosis and the Bcl-2 gene family -- patterns of expression and prognostic value in stage I and II follicular center lymphoma.

T. McDonnell, L. Peters, J. Cox, 1999, International journal of radiation oncology, biology, physics.

Marginal zone lymphomas

P. Iyengar, P. Mclaughlin, F. Cabanillas, 2010, Cancer.

Outcome with the hyper-CVAD regimens in lymphoblastic lymphoma.

H. Kantarjian, J. Cortes, S. Verstovsek, 2004, Blood.

Trimetrexate in relapsed T-cell lymphoma with skin involvement.

P. Mclaughlin, F. Cabanillas, L. Medeiros, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Paclitaxel plus topotecan treatment for patients with relapsed or refractory aggressive non-Hodgkin's lymphoma.

P. Mclaughlin, F. Cabanillas, F. Cabanillas, 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

Nasal-Type T/NK Lymphomas: A Clinicopathologic Study of 13 Cases

J. Manning, F. Cabanillas, F. Ravandi, 2000, Leukemia & lymphoma.

The outcome of combined-modality treatments for stage I and II primary large B-cell lymphoma of the mediastinum.

J. Manning, J. Cox, F. Cabanillas, 2000, International journal of radiation oncology, biology, physics.

Ninety-six-hour paclitaxel infusion with mitoxantrone and ifosfamide/mesna and consolidation with ESHAP for refractory and relapsed non-Hodgkin's lymphoma.

P. Mclaughlin, F. Cabanillas, A. Sarris, 1998, Leukemia & lymphoma.

Paclitaxel plus high‐dose cyclosphosphamide with G‐CSF support in patients with relapsed and refractory aggressive non‐Hodgkin's lymphoma

P. Mclaughlin, F. Cabanillas, A. Younes, 1998, British journal of haematology.

Soluble CD95 in the serum of patients with low and intermediate grade malignant lymphomas: absence of prognostic correlations.

M. Andreeff, F. Cabanillas, A. Younes, 1997, Leukemia & lymphoma.

Primary parotid lymphoma: the effect of International Prognostic Index on outcome.

P. Mclaughlin, J. Cox, F. Cabanillas, 1997, Leukemia & lymphoma.

Ten‐year follow‐up after intense chemoimmunotherapy with Rituximab‐HyperCVAD alternating with Rituximab‐high dose methotrexate/cytarabine (R‐MA) and without stem cell transplantation in patients with untreated aggressive mantle cell lymphoma

Michael L. Wang, H. Kantarjian, P. Mclaughlin, 2010, British journal of haematology.

Phase 2 trial of rituximab plus hyper‐CVAD alternating with rituximab plus methotrexate‐cytarabine for relapsed or refractory aggressive mantle cell lymphoma

Michael L. Wang, Maria A. Rodriguez, H. Kantarjian, 2008, Cancer.

Phase II Study of Paclitaxel in Combination with Mitoxantrone and Ifosfamide/Mesna for Patients with Relapsed or Refractory Non-Hodgkin's Lymphoma after Failure to Cytarabine/Cisplatin Combination

P. Mclaughlin, F. Cabanillas, A. Younes, 1999, Investigational New Drugs.

Follicular large cell lymphoma: analysis and prognostic factors in 62 patients.

H. Kantarjian, L. Fuller, P. Mclaughlin, 1984, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Gallium Scan after the Second and Fourth Chemotherapy Cycle is Predictive in Aggressive Non-Hodgkin ’ s Lymphomas

Maria A. Rodriguez, D. Podoloff, P. Mclaughlin, 2012 .

Intensive dose ifosfamide and etoposide with G-CSF for stem cell mobilization in patients with non-Hodgkin's lymphoma.

P. Mclaughlin, F. Cabanillas, A. Younes, 1999, Leukemia & lymphoma.

Alternating triple therapy for the treatment of intermediate grade and immunoblastic lymphoma.

P. Mclaughlin, F. Cabanillas, F. Hagemeister, 1998, Annals of oncology : official journal of the European Society for Medical Oncology.

CD30 ligand in lymphoma patients with CD30+ tumors.

K. Kliche, M. Andreeff, F. Cabanillas, 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Lymphomatous presentation of CD4+/CD8+ HTLV-1-related adult T-cell leukemia/lymphoma in an Iranian woman.

F. Cabanillas, A. Younes, J. Seymour, 1994, Leukemia & lymphoma.

Calcitriol Production in Hypercalcemic and Normocalcemic Patients with Non-Hodgkin Lymphoma

F. Cabanillas, J. Seymour, F. Hagemeister, 1994, Annals of Internal Medicine.

Cyclosporin A does not reverse clinical resistance to paclitaxel in patients with relapsed non-Hodgkin's lymphoma.

P. Mclaughlin, L. North, F. Cabanillas, 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Central lymphatic irradiation for stage I-III follicular lymphoma: report from a single-institutional prospective study.

S. Tucker, P. Mclaughlin, J. Cox, 2001, International journal of radiation oncology, biology, physics.

Stage III follicular lymphoma: long-term follow-up and patterns of failure.

S. Tucker, P. Mclaughlin, J. Cox, 2003, International journal of radiation oncology, biology, physics.

Activity of TNF‐related apoptosis‐inducing ligand (TRAIL) in haematological malignancies

M. Andreeff, F. Cabanillas, A. Younes, 1997, British journal of haematology.

Human B cell lymphomas: in vitro and in vivo studies on growth factors and cell growth.

F. Cabanillas, R. Ford, D. Li, 1993, Leukemia & lymphoma.

Second Malignancies After Chemotherapy and Radiotherapy for Hodgkin Disease

Maria A. Rodriguez, L. Levy, E. Atkinson, 2004, American journal of clinical oncology.

High-dose cyclophosphamide, carmustine, and etoposide and autologous bone marrow transplantation for relapsed Hodgkin's disease.

J. Armitage, S. Jagannath, A. Zander, 1986, Annals of internal medicine.

High ten‐year remission rates following rituximab, fludarabine, mitoxantrone and dexamethasone (R‐FND) with interferon maintenance in indolent lymphoma: Results of a randomized Study

Michael L. Wang, Maria A. Rodriguez, Y. Oki, 2017, British journal of haematology.

A phase I/II trial of pixantrone (BBR2778), methylprednisolone, cisplatin, and cytosine arabinoside (PSHAP) in relapsed/refractory aggressive non-Hodgkin's lymphoma

A. Tulpule, F. Cabanillas, L. Fayad, 2007, Leukemia & lymphoma.

Localized primary non-Hodgkin lymphoma of the breast.

J. Cox, F. Cabanillas, C. Ha, 1998, American journal of clinical oncology.

Anaplastic Lymphoma Kinase (ALK) is not Expressed in Hodgkin's Disease: Results with ALK-11 Antibody in 327 Untreated Patients

F. Cabanillas, G. Rassidakis, L. Medeiros, 2001, Leukemia & lymphoma.

Can we cure indolent lymphomas?

F. Cabanillas, 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

Technical Advance Novel 5 9 Exonuclease-Based Real-Time PCR Assay for the Detection of t(14;18)(q32;q21) in Patients with Follicular Lymphoma

F. Cabanillas, A. Sarris, R. Luthra, 1998 .

Functional expression of receptor activator of nuclear factor kappaB in Hodgkin disease cell lines.

B. Aggarwal, A. Gillenwater, F. Cabanillas, 2001, Blood.

Intensive induction chemotherapy of extensive small cell bronchogenic carcinoma in protected environment--prophylactic antibiotic units. A preliminary report.

F. Cabanillas, C. Mountain, G. Bodey, 1980, International journal of radiation oncology, biology, physics.

Post‐Therapy CT‐Detected Mass in Lymphoma Patients: Is It Viable Tissue?

M. Bernardino, F. Cabanillas, P. Salvador, 1982, Journal of computer assisted tomography.

Chromosomal abnormalities in adult non‐endemic burkitt's lymphoma and leukemia: 22 new reports and a review of 148 cases from the literature

F. Cabanillas, S. Kornblau, A. Goodacre, 2006, Hematological oncology.

Asymptomatic Waldenstrom's macroglobulinemia.

F. Cabanillas, D. Weber, R. Alexanian, 2003, Seminars in oncology.

Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group.

J. Armitage, J. Vose, A. Hagenbeek, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A New Salvage Regimen for Aggressive Lymphomas Based on Gemcitabine, Rituximab, and Oxaliplatin Followed by Lenalidomide (GROC-Rev).

F. Cabanillas, C. Rivera, Noridza Rivera, 2019, Clinical lymphoma, myeloma & leukemia.

The addition of rituximab to CHOP chemotherapy improves overall and failure-free survival for follicular grade 3 lymphoma.

P. Mclaughlin, F. Cabanillas, M. Overman, 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

A prospective randomized study to compare the molecular response rates between central lymphatic irradiation and intensive alternating triple chemotherapy in the treatment of stage I-III follicular lymphoma.

Maria A. Rodriguez, S. Tucker, P. Mclaughlin, 2003, International journal of radiation oncology, biology, physics.

Long-Term F ollow-Up o f a P rospective S tudy o f C ombined Modality T herapy f or S tage I -II I ndolent N on-Hodgkin's Lymphoma

Maria A. Rodriguez, L. Fuller, P. Mclaughlin, 2003 .

NCCN preliminary non-Hodgkin's lymphoma practice guidelines.

J. Vose, A. Zelenetz, Maria A. Rodriguez, 1997, Oncology.

Safety of fludarabine, mitoxantrone, and dexamethasone combined with rituximab in the treatment of stage IV indolent lymphoma.

P. Mclaughlin, F. Cabanillas, A. Younes, 2000, Seminars in oncology.

Chromosome 17p and p53 changes in lymphoma

F. Cabanillas, A. Deisseroth, A. Goodacre, 1991, British journal of haematology.

Comparison of lymphangiograms and gallium scans in the non‐Hodgkin's lymphomas

F. Cabanillas, T. Haynie, V. Rodriguez, 1977, Cancer.

High dose therapy and autologous marrow transplantation as salvage treatment for patients with diffuse large cell lymphoma.

J. Armitage, P. Bierman, S. Jagannath, 1986, European journal of cancer & clinical oncology.

Dose dense CHOP: When more is not always better!

F. Cabanillas, 2007, Leukemia & lymphoma.

A pilot study of high-dose interleukin-3 treatment of relapsed follicular small cleaved-cell lymphoma: hematologic, immunologic, and clinical results.

M. Andreeff, P. Mclaughlin, F. Cabanillas, 1996, Blood.

No effect of 96-hour paclitaxel infusion in patients with relapsed non-Hodgkin's lymphoma refractory to a 3-hour infusion schedule.

P. Mclaughlin, F. Cabanillas, A. Younes, 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Front-line immunochemotherapy for aggressive non-Hodgkin lymphoma using dose-dense rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone plus granulocyte-macrophage colony stimulating factor and pegfi lgrastim as support

F. Cabanillas, M. Cotto, I. Liboy, 2012, Leukemia & lymphoma.

Outcome of Hodgkin's disease in elderly patients

F. Cabanillas, F. Hagemeister, F. Hagemeister, 1995, Hematological oncology.

Indolent Lymphomas That Present With Clinically Aggressive Features: A Subset of Low-Grade Lymphomas With a Behavior Inconsistent With the Histologic Diagnosis.

F. Cabanillas, Noridza Rivera, Wandaly I. Pardo, 2016, Clinical lymphoma, myeloma & leukemia.

Diagnosis of leukemia or lymphoma in the central nervous system by beta 2-microglobulin determination.

W. Tourtellotte, F. Cabanillas, S. Schold, 1980, The New England journal of medicine.

Fludarabine, mitoxantrone, and dexamethasone: an effective new regimen for indolent lymphoma.

P. Mclaughlin, F. Cabanillas, F. Cabanillas, 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Long-term follow-up of platinum-based lymphoma salvage regimens. The M.D. Anderson Cancer Center experience.

F. Cabanillas, F. Cabanillas, E. Rodriguez-Monge, 1997, Hematology/oncology clinics of North America.

Follicular large cell lymphoma: An aggressive lymphoma that often presents with favorable prognostic features

Maria A. Rodriguez, P. Mclaughlin, F. Cabanillas, 1999 .

Hodgkin's disease with lymphocyte predominance: long-term results based on current histopathologic criteria.

L. Fuller, P. Mclaughlin, J. Cox, 1999, International journal of radiation oncology, biology, physics.

Recombinant human granulocyte colony-stimulating factor hastens granulocyte recovery after high-dose chemotherapy and autologous bone marrow transplantation in Hodgkin's disease.

S. Jagannath, S. Tucker, F. Cabanillas, 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Rising serum lactate dehydrogenase often caused by granulocyte-or Granulocyte-macrophage colony stimulating factor and not tumor progression in patients with lymphoma or myeloma.

F. Cabanillas, A. Younes, M. Rodriguez, 1995, Leukemia & lymphoma.

Endocrine characterization of primary mediastinal lymphoma.

F. Cabanillas, J. Romaguera, T. Brooks, 1996, Leukemia & lymphoma.

Prognostic value of serum CD44, intercellular adhesion molecule-1 and vascular cell adhesion molecule-1 levels in patients with indolent non-Hodgkin lymphomas

Maria A. Rodriguez, P. Mclaughlin, F. Cabanillas, 2012, Leukemia & lymphoma.

High incidence of non-neutropenic infections induced by rituximab plus fludarabine and associated with hypogammaglobulinemia: a frequently unrecognized and easily treatable complication.

F. Cabanillas, I. Liboy, E. Rivera, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

Linfoma No Hodgkin

M. Caligiuri, A. Zelenetz, M. Czuczman, 2005 .

Human central nervous system pharmacology of pentamethylmelamine and its metabolites

R. Benjamin, F. Cabanillas, D. Stewart, 2004, Journal of Neuro-Oncology.

Experience with 9-Cis Retinoic Acid in Patients with Relapsed and Refractory Non-Hodgkin's Lymphoma

P. Mclaughlin, F. Cabanillas, M. Cristofanilli, 2000, Leukemia & lymphoma.

Unbalanced expression of Fas and CD40 in mantle cell lymphoma

S. Zhao, M. Andreeff, F. Cabanillas, 1998, British journal of haematology.

Analysis of p53 gene deletions in patients with non‐Hodgkin's lymphoma by dual‐colour fluorescence in‐situ hybridization

M. Andreeff, F. Cabanillas, A. Younes, 1997, British journal of haematology.

Chemotherapy as definitive treatment of stage I‐II large cell and diffuse mixed lymphomas

F. Cabanillas, 1985, Hematological oncology.

Anaplastic Ki-1 + large-cell lymphoma.

F. Cabanillas, J. Romaguera, W. Pugh, 1993, Cancer investigation.

Managing Indolent Lymphomas in Relapse

M. Kaminski, S. Horning, F. Cabanillas, 2000 .

Managing Indolent Lymphomas in Relapse: Working Our Way Through a Plethora of Options.

M. Kaminski, S. Horning, F. Cabanillas, 2000, Hematology. American Society of Hematology. Education Program.

Expression of CD40 ligand (CD154) in B and T lymphocytes of Hodgkin disease

M. Andreeff, F. Cabanillas, A. Younes, 2002, Cancer.

Interleukin-13 levels in serum from patients with Hodgkin disease and healthy volunteers.

F. Cabanillas, A. Younes, P. Fiumara, 2001, Blood.

Sphingosomal vincristine in CHOP is a promising new treatment for elderly, as well as poor prognosis patients with aggressive non-Hodgkin's lymphoma (NHL): Follow-up results of a phase II study

Maria A. Rodriguez, F. Cabanillas, N. Dang, 2004 .

Sphingosomal vincristine in CHOP is a promising new treatment for elderly, as well as poor prognosis patients with aggressive non-Hodgkin's lymphoma (NHL): Follow-up results of a phase II study.

F. Cabanillas, N. Dang, L. Fayad, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prognostic significance of MUC-1 expression in systemic anaplastic large cell lymphoma.

F. Cabanillas, G. Rassidakis, L. Medeiros, 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

Lymphomatoid Papulosis: A T-Cell Dyscrasia with a Propensity To Transform into Malignant Lymphoma

D. Weisenburger, F. Cabanillas, M. Duvic, 1995, Annals of Internal Medicine.

The expanding role of fludarabine in hematologic malignancies.

V. Grégoire, H. Kantarjian, P. Mclaughlin, 1994, Leukemia & lymphoma.

Apoptotic induction in transformed follicular lymphoma cells by Bcl-2 downregulation.

M. Tormo, J. Garcia-conde, T. McDonnell, 1998, Leukemia & lymphoma.

Hodgkin's disease variant of Richter's syndrome: experience at a single institution.

J. Manning, F. Cabanillas, M. Keating, 1996, Leukemia & lymphoma.

Alterations in tretinoin pharmacokinetics following administration of liposomal all-trans retinoic acid.

P. Thall, E. Estey, R. Kurzrock, 1996, Blood.

Real-Time Polymerase Chain Reaction of Genomic DNA for Quantitation of t(14;18)

F. Cabanillas, A. Sarris, Apostolia M Tsimberidou, 2003 .

Quantitative real-time polymerase chain reaction for monitoring minimal residual disease in patients with advanced indolent lymphomas treated with rituximab, fludarabine, mitoxantrone, and dexamethasone.

P. Mclaughlin, F. Cabanillas, G. Rassidakis, 2002, Seminars in oncology.

Intensive conventional-dose chemotherapy for stage IV low-grade lymphoma: high remission rates and reversion to negative of peripheral blood bcl-2 rearrangement.

P. Mclaughlin, F. Cabanillas, A. Sarris, 1994, Annals of oncology : official journal of the European Society for Medical Oncology.

Identification of B-cell growth factors (interleukin-14; high molecular weight-B-cell growth factors) in effusion fluids from patients with aggressive B-cell lymphomas.

F. Cabanillas, J. Ambrus, R. Ford, 1995, Blood.

NOVP and radiotherapy for early-staged Hodgkin's disease: an interim analysis.

L. Fuller, P. Mclaughlin, F. Cabanillas, 1992, Annals of oncology : official journal of the European Society for Medical Oncology.

Evidence for the efficacy of Iniparib, a PARP-1 inhibitor, in BRCA2-associated pancreatic cancer.

S. Kopetz, R. Wolff, F. Cabanillas, 2011, Anticancer research.

CD30 ligand is expressed on resting normal and malignant human B lymphocytes

M. Andreeff, F. Cabanillas, A. Younes, 1996, British journal of haematology.

Incidence and Risk Factors for Developing Herpes Zoster Among a Cohort of Patients Diagnosed With Lymphoma at a Community Cancer Center

F. Cabanillas, Yamila Goenaga Vázquez, J. Concepción, 2018, Clinical lymphoma, myeloma & leukemia.

High-dose combination chemotherapy with cyclophosphamide, carmustine, etoposide, and autologous bone marrow transplantation in 60 patients with relapsed Hodgkin's disease: the M. D. Anderson experience.

S. Jagannath, F. Cabanillas, J. Spinolo, 1989, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

Expression of CD26 and its associated dipeptidyl peptidase IV enzyme activity enhances sensitivity to doxorubicin-induced cell cycle arrest at the G(2)/M checkpoint.

G. Mills, F. Cabanillas, C. Morimoto, 2001, Cancer research.

In vitro and in vivo antitumor effect of the anti-CD26 monoclonal antibody 1F7 on human CD30+ anaplastic large cell T-cell lymphoma Karpas 299.

G. Mills, F. Cabanillas, J. Abbruzzese, 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

M Checkpoint 2 Cell Cycle Arrest at the G Enzyme Activity Enhances Sensitivity to Doxorubicin-induced Expression of CD 26 and Its Associated Dipeptidyl Peptidase IV Updated

F. Cabanillas, C. Morimoto, K. Ohnuma, 2001 .

In Vitro and in Vivo Antitumor Effect of the Anti-CD 26 Monoclonal Antibody 1 F 7 on Human CD 30 1 Anaplastic Large Cell T-Cell Lymphoma Karpas 2991

G. Mills, F. Cabanillas, J. Abbruzzese, 2001 .

Expression of CD 26 and Its Associated Dipeptidyl Peptidase IV Enzyme Activity Enhances Sensitivity to Doxorubicin-induced Cell Cycle Arrest at the G 2 / M Checkpoint 1

G. Mills, Kazuya Sato, F. Cabanillas, 2001 .

Prognostic factors with high-dose melphalan for refractory multiple myeloma [see comments]

B. Barlogie, B. Cheson, F. Cabanillas, 1988 .

CD 30-ligand and CD 40-ligand expression in lymph nodes involved with Hodgkin ' s disease

S. Zhao, K. Kliche, M. Andreeff, 2005 .

CD30-ligand and CD40-ligand expression in lymph nodes involved with Hodgkin's disease.

S. Zhao, K. Kliche, M. Andreeff, 1997, Annals of oncology : official journal of the European Society for Medical Oncology.

Allogeneic stem cell transplantation with fludarabine-based, less intensive conditioning regimens as adoptive immunotherapy in advanced Hodgkin's disease

P. Mclaughlin, J. Manning, F. Cabanillas, 2000, Bone Marrow Transplantation.

Rapid recovery of spermatogenesis after mitoxantrone, vincristine, vinblastine, and prednisone chemotherapy for Hodgkin's disease.

L. Fuller, F. Cabanillas, F. Cabanillas, 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

MINE-ESHAP salvage therapy for recurrent and refractory lymphomas.

F. Cabanillas, M. Rodriguez, 1994, Seminars in hematology.

Recent trends in the management of lymphomas at M.D. Anderson Cancer Center.

F. Cabanillas, M. Rodriguez, F. Swan, 1990, Seminars in oncology.

Experience with salvage regimens at M.D. Anderson Hospital.

F. Cabanillas, 1991, Annals of oncology : official journal of the European Society for Medical Oncology.

Quantitative Real-Time Polymerase Chain Reaction for Detection of Circulating Cells with T(14;18) in Volunteer Blood Donors and Patients with Follicular Lymphoma

P. Mclaughlin, F. Cabanillas, A. Tsimberidou, 2002, Leukemia & lymphoma.

Hematologic recovery after central lymphatic irradiation for patients with stage I–III follicular lymphoma

S. Tucker, P. Mclaughlin, F. Cabanillas, 2001, Cancer.

Growth inhibition of follicular small-cleaved-cell lymphoma cells in short-term culture by interleukin-3.

F. Cabanillas, A. Younes, A. Sarris, 1994, Annals of oncology : official journal of the European Society for Medical Oncology.

liposomal all-trans retinoic acid Alterations in tretinoin pharmacokinetics following administration of

P. Thall, E. Estey, R. Kurzrock, 2011 .

Serial determination of the bcl-2 gene in the bone marrow and peripheral blood after central lymphatic irradiation for stages I-III follicular lymphoma: a preliminary report.

P. Mclaughlin, J. Cox, F. Cabanillas, 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

Transformation of follicular lymphoma. Expression of p53 and bcl-2 oncoprotein, apoptosis and cell proliferation.

W. Symmans, F. Cabanillas, N. Ordóñez, 1995, Acta cytologica.

Paclitaxel activity for the treatment of non‐Hodgkin's lymphoma: final report of a phase II trial

R. Kurzrock, P. Mclaughlin, L. North, 1997, British journal of haematology.

Pulmonary changes in patients with lymphoma who receive paclitaxel.

L. North, F. Cabanillas, A. Younes, 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Etoposide, dexamethasone, cytarabine, and cisplatin in vincristine, doxorubicin, and dexamethasone-refractory myeloma.

B. Barlogie, W. Velasquez, F. Cabanillas, 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase 2 study of fludarabine and paclitaxel in patients with recurrent low-grade non-Hodgkin's lymphoma

P. Mclaughlin, F. Cabanillas, A. Younes, 2006, Leukemia & lymphoma.

Commentary (Cabanillas)—Follicular Lymphoma: Expanding Therapeutic Options

F. Cabanillas, 2005 .

Long‐term outcomes, secondary malignancies and stem cell collection following bendamustine in patients with previously treated non‐Hodgkin lymphoma

A. LaCasce, J. Friedberg, J. Leonard, 2017, British journal of haematology.

Establishment and characterization of human B-cell lymphoma cell lines using B-cell growth factor

F. Cabanillas, A. Goodacre, R. Ford, 1990 .

Follicular large cell lymphoma

P. Mclaughlin, F. Cabanillas, L. Fayad, 1999 .

How important is whole brain radiotherapy for treatment of primary CNS lymphoma?

F. Cabanillas, 2010, The Lancet. Oncology.

9-β-D-Arabinofuranosyl-2-fluoroadenine 5′-monophosphate pharmacokinetics in plasma and tumor cells of patients with relapsed leukemia and lymphoma

F. Cabanillas, W. Plunkett, M. Keating, 1986, Cancer Chemotherapy and Pharmacology.

Randomized trial of beta-lactam regimens in febrile neutropenic cancer patients.

E. Anaissie, H. Kantarjian, L. Elting, 1988, The American journal of medicine.

A progressive blistering eruption in a patient with lymphoma. Paraneoplastic pemphigus.

J. Herrada, F. Cabanillas, R. Jordon, 1997, Archives of dermatology.

Protected environment-prophylactic antibiotic program for malignant lymphoma. Randomized trial during chemotherapy to induce remission.

F. Cabanillas, E. Freireich, G. Bodey, 1979, The American journal of medicine.

β‐Lactam regimens for the febrile neutropenic patient

E. Anaissie, H. Kantarjian, L. Elting, 1990 .

Therapeutic and prognostic implications of peripheral blood lymphopenia in patients with Hodgkin's disease.

F. Cabanillas, A. Younes, J. Ayoub, 1999, Leukemia & lymphoma.

Phase II study of a high-dose ifosfamide-based chemotherapy regimen with growth factor rescue in recurrent aggressive NHL. High response rates and limited toxicity, but limited impact on long-term survival

S. Tomany, F. Cabanillas, A. Younes, 2001, Bone Marrow Transplantation.

CD26 in T-cell lymphomas: a potential clinical role?

S. Verstovsek, F. Cabanillas, N. Dang, 2000, Oncology.

Overview of prognostic factors in non-Hodgkin's lymphoma.

D. Moore, F. Cabanillas, F. Cabanillas, 1998, Oncology.

Vitamin C and cancer: what can we conclude--1,609 patients and 33 years later?

F. Cabanillas, 2010, Puerto Rico health sciences journal.

Leukocyte interferon-induced tumor regression in human metastatic breast cancer, multiple myeloma, and malignant lymphoma.

S. Pestka, G. Hortobagyi, A. Buzdar, 1980, Annals of internal medicine.

Rectal adenocarcinoma: proposal for a model based on pretreatment prognostic factors.

F. Cabanillas, I. Echenique, M. Nieves-Plaza, 2012, Puerto Rico health sciences journal.

Phase II Clinical Trial of Interleukin-12 in Patients with Relapsed and Refractory Non-Hodgkin’s Lymphoma and Hodgkin’s Disease

I. Flinn, P. Mclaughlin, F. Cabanillas, 2004, Clinical Cancer Research.

Initial experience with AMSA as single agent treatment against malignant lymphoproliferative disorders.

F. Cabanillas, E. Freireich, S. Legha, 1981, Blood.

Clinical and Preclinical Pharmacology of Liposomal Vincristine

F. Cabanillas, M. Bally, L. Mayer, 2000 .

Fludarabine--present status and future developments in chronic lymphocytic leukemia and lymphoma.

V. Grégoire, P. Mclaughlin, F. Cabanillas, 1994, Annals of oncology : official journal of the European Society for Medical Oncology.

9-beta-D-arabinofuranosyl-2-fluoroadenine 5'-monophosphate pharmacokinetics in plasma and tumor cells of patients with relapsed leukemia and lymphoma.

F. Cabanillas, W. Plunkett, M. Keating, 1986, Cancer chemotherapy and pharmacology.

Chemoimmunotherapy with hyper‐CVAD plus rituximab for the treatment of adult Burkitt and Burkitt‐type lymphoma or acute lymphoblastic leukemia

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2006, Cancer.

High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine.

Michael L. Wang, P. Mclaughlin, F. Cabanillas, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Richter's syndrome: a report on 39 patients.

H. Kantarjian, P. Mclaughlin, F. Cabanillas, 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Elevated Serum Levels of IL-10 are Associated with Inferior Progression-Free Survival in Patients with Hodgkin's Disease Treated with Radiotherapy

K. Kliche, G. Bonadonna, F. Cabanillas, 2004, Leukemia & lymphoma.

Interleukin-10 levels are often elevated in serum of adults with Hodgkin's disease and are associated with inferior failure-free survival.

K. Kliche, M. Andreeff, S. Tucker, 1999, Annals of oncology : official journal of the European Society for Medical Oncology.

Long-term follow-up with ABDIC salvage chemotherapy of MOPP-resistant Hodgkin's disease.

F. Cabanillas, F. Cabanillas, N. Tannir, 1983, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Hyper-CVAD program in Burkitt's-type adult acute lymphoblastic leukemia.

H. Kantarjian, J. Cortes, F. Cabanillas, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Metabolic abnormalities in lymphoma.

F. Cabanillas, 2002, Clinical lymphoma.

Tumor Necrosis Factor-α and Interferon-γ, but not HTLV-I Tax, are Likely Factors in the Epidermotropism of Cutaneous T-Cell Lymphoma via Induction of Interferon-Inducible Protein-10

F. Cabanillas, A. Sarris, B. Gansbacher, 1998 .

Mantle irradiation alone for pathologic stage I and II Hodgkin's disease: long-term follow-up and patterns of failure.

Z. Liao, S. Tucker, J. Cox, 2001, International journal of radiation oncology, biology, physics.

Long-term outcome of treatment for Ann Arbor Stage I Hodgkin's disease: prognostic factors for survival and freedom from progression.

L. Fuller, J. Cox, B. Brown, 1997, International journal of radiation oncology, biology, physics.

Sequential chemotherapy and late intensification for malignant lymphomas of aggressive histologic type.

F. Cabanillas, E. Freireich, G. Bodey, 1983, American Journal of Medicine.

Factors predicting for response and survival in adults with advanced non-Hodgkin's lymphoma.

F. Cabanillas, J. Butler, V. Rodriguez, 1978, Archives of internal medicine.

Long-term results with radiotherapy for Stage I-II follicular lymphomas.

S. Tucker, L. Fuller, P. Mclaughlin, 2001, International journal of radiation oncology, biology, physics.

MIME chemotherapy (methyl-GAG, ifosfamide, methotrexate, etoposide) as treatment for recurrent Hodgkin's disease.

W. Velasquez, P. Mclaughlin, F. Cabanillas, 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Follicular large cell lymphoma: long-term follow-up of 62 patients treated between 1973-1981.

H. Kantarjian, P. Mclaughlin, F. Cabanillas, 2000, Annals of oncology : official journal of the European Society for Medical Oncology.

Follicular large cell lymphoma: an aggressive lymphoma that often presents with favorable prognostic features.

P. Mclaughlin, F. Cabanillas, F. Cabanillas, 1999, Blood.

Nodular malignant lymphomas. Factors affecting complete response rate and survival

F. Cabanillas, J. Gutterman, E. Freireich, 1979, Cancer.

Central nervous system relapse in malignant lymphomas: risk factors and implications for prophylaxis.

F. Cabanillas, E. Freireich, G. Bodey, 1979, Blood.

Refractoriness to chemotherapy and poor survival related to abnormalities of chromosomes 17 and 7 in lymphoma.

F. Cabanillas, S. Pathak, A. Cork, 1989, The American journal of medicine.

Primary cutaneous non-Hodgkin's lymphoma with aggressive histology: inferior outcome is associated with peripheral T-cell type and elevated lactate dehydrogenase, but not extent of cutaneous involvement.

P. Mclaughlin, F. Cabanillas, L. Medeiros, 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

Primary cutaneous non-Hodgkin's lymphoma of Ann Arbor stage I: preferential cutaneous relapses but high cure rate with doxorubicin-based therapy.

P. Mclaughlin, F. Cabanillas, J. Cox, 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Primary C utaneous N on-Hodgkin's L ymphoma o f A nn A rbor Stage I : P referential C utaneous R elapses b ut H igh C ure Rate W ith D oxorubicin-Base d T herapy

P. Mclaughlin, J. Cox, F. Cabanillas, 2001 .

Interferon-inducible protein 10 as a possible factor in the pathogenesis of cutaneous T-cell lymphomas.

A. Zelenetz, M. Reiss, F. Cabanillas, 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

Interferon-inducible protein-10 and the pathogenesis of cutaneous T-cell lymphomas.

M. Reiss, F. Cabanillas, A. Deisseroth, 1996, Leukemia & lymphoma.

BAX expression in Hodgkin and Reed-Sternberg cells of Hodgkin's disease: correlation with clinical outcome.

T. McDonnell, G. Bonadonna, F. Cabanillas, 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

Lymphomas The Clinical Significance of Molecular Response in Indolent Follicular

A. López-Guillermo, P. Mclaughlin, F. Cabanillas, 2013 .

Correlation of bcl-2 rearrangement with clinical characteristics and outcome in indolent follicular lymphoma.

A. López-Guillermo, P. Mclaughlin, F. Cabanillas, 1999, Blood.

The clinical significance of molecular response in indolent follicular lymphomas.

A. López-Guillermo, P. Mclaughlin, F. Cabanillas, 1998, Blood.

Prognostic factors for disease progression after high-dose chemotherapy and autologous hematopoietic stem cell transplantation for recurrent or refractory Hodgkin's lymphoma

J. Cox, F. Cabanillas, B. Andersson, 2004, Bone Marrow Transplantation.

Expression of Epstein-Barr virus latent membrane protein-1 in Hodgkin and Reed-Sternberg cells of classical Hodgkin's lymphoma: associations with presenting features, serum interleukin 10 levels, and clinical outcome.

K. Kliche, G. Bonadonna, F. Cabanillas, 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

Expression of Epstein-Barr Virus Latent Membrane Protein-1 in Hodgkin and Reed-Sternberg Cells of Classical Hodgkin ’ s Lymphoma : Associations with Presenting Features , Serum Interleukin 10 Levels , and Clinical Outcome 1

K. Kliche, G. Bonadonna, F. Cabanillas, 2003 .

BCL-2 expression in Hodgkin and Reed-Sternberg cells of classical Hodgkin disease predicts a poorer prognosis in patients treated with ABVD or equivalent regimens.

T. McDonnell, G. Bonadonna, F. Cabanillas, 2002, Blood.

CD20 expression in Hodgkin and Reed-Sternberg cells of classical Hodgkin's disease: associations with presenting features and clinical outcome.

G. Bonadonna, P. Mclaughlin, F. Cabanillas, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A new chemotherapy regimen for treatment of Hodgkin's disease associated with minimal genotoxicity.

G. J. Gabriel, M. Kattan, L. Fuller, 1993, Leukemia & lymphoma.

Original article: Two cycles of MOPP and radiotherapy: Effective treatment for stage IIIA and IIIB Hodgkin's disease

W. Velasquez, L. Fuller, P. Mclaughlin, 1991 .

Reporting outcomes in Hodgkin's disease and lymphoma.

E. Gehan, L. Fuller, P. Mclaughlin, 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Lymphoma classification--the gap between biology and clinical management is closing.

W Hiddemann, J. Armitage, F. Cavalli, 1996, Blood.

Irinotecan in relapsed or refractory non-Hodgkin's lymphomas. Indications of activity in a phase II trial.

A. Bleyer, F. Cabanillas, L. Medeiros, 2002, Oncology.

The significance of molecular response of follicular lymphoma to central lymphatic irradiation as measured by polymerase chain reaction for t(14;18)(q32;q21).

S. Tucker, P. Mclaughlin, J. Cox, 2001, International journal of radiation oncology, biology, physics.

Molecular response assessed by PCR is the most important factor predicting failure-free survival in indolent follicular lymphoma: update of the MDACC series.

A. López-Guillermo, P. Mclaughlin, F. Cabanillas, 2000, Annals of oncology : official journal of the European Society for Medical Oncology.

The clinical relevance of t(14;18)/BCL-2 rearrangement and DEL 6q in diffuse large cell lymphoma and immunoblastic lymphoma.

F. Cabanillas, A. Goodacre, J. Romaguera, 1993, Annals of oncology : official journal of the European Society for Medical Oncology.

IMVP-16: an effective regimen for patients with lymphoma who have relapsed after initial combination chemotherapy.

F. Cabanillas, E. Freireich, G. Bodey, 1982, Blood.

Long-term follow-up of a prospective study of combined modality therapy for stage I-II indolent non-Hodgkin's lymphoma.

Terry L. Smith, L. Fuller, P. Mclaughlin, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The hematologic malignancies: Leukemia, lymphoma, and myeloma

B. Barlogie, F. Cabanillas, E. Freireich, 1984, Cancer.

Risk factors, treatment, and outcome of central nervous system recurrence in adults with intermediate-grade and immunoblastic lymphoma.

P. Mclaughlin, J. Cox, F. Cabanillas, 1998, Blood.

Advances in Diagnosis and Management of Diffuse Large B‐cell Lymphoma

F. Cabanillas, B. Shah, 2017, Clinical lymphoma, myeloma & leukemia.

Historical Perspective on the Treatment Challenges of Low-Grade Non-Hodgkin’s Lymphoma

F. Cabanillas, 2007 .

ESHAP--an effective chemotherapy regimen in refractory and relapsing lymphoma: a 4-year follow-up study.

S. Tucker, W. Velasquez, P. Mclaughlin, 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

graft-versus-host disease, and treatment-related mortality immunotherapy for indolent lymphoma: low incidence of toxicity, acute Nonablative allogeneic hematopoietic transplantation as adoptive

P. Mclaughlin, F. Cabanillas, A. Younes, 2013 .

Improvement in complete response rate, duration of response and survival with adriamycin combination chemotherapy for non-Hodgkin lymphoma: a prognostic factor comparison of two regimens.

F. Cabanillas, E. Freireich, V. Rodriguez, 1978, Medical and pediatric oncology.

lymphoma alternating triple therapy (ATT) regimen in patients with stage IV indolent Fludarabine, mitoxantrone, dexamethasone (FND) compared with an

P. Mclaughlin, F. Cabanillas, A. Tsimberidou, 2013 .

Very high levels of soluble CD30 recognize the patients with classical Hodgkin's lymphoma retaining a very poor prognosis

M. Federico, F. Cabanillas, G. Pangalis, 2006, European journal of haematology.

Analysis of in-field control and late toxicity for adults with early-stage Hodgkin's disease treated with chemotherapy followed by radiotherapy.

S. Tucker, J. Cox, F. Cabanillas, 2003, International journal of radiation oncology, biology, physics.

Clinical stage IEA-IIEA orbital lymphomas: outcomes in the era of modern staging and treatment.

C. Pelloski, J. Cox, F. Cabanillas, 2001, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Impact of involved field radiotherapy after CHOP-based chemotherapy on stage III-IV, intermediate grade and large-cell immunoblastic lymphomas.

S. Tucker, J. Cox, F. Cabanillas, 2000, International journal of radiation oncology, biology, physics.

Prognostic Value of Serum Interleukin-6 in Diffuse Large-cell Lymphoma

R. Kurzrock, F. Cabanillas, M. Talpaz, 1997, Annals of Internal Medicine.

Localized primary malignant lymphoma of bone.

J. Murray, L. Fuller, J. Cox, 1997, International journal of radiation oncology, biology, physics.

Cisplatin-CBV with autologous bone marrow transplantation for relapsed Hodgkin's disease.

S. Jagannath, F. Cabanillas, J. Spinolo, 1993, Leukemia & lymphoma.

Phase I trial of pentamethylmelamine.

J. Ajani, F. Cabanillas, G. Bodey, 1982, Cancer treatment reports.

Detection of Chromosome 11 q 13 Breakpoints by Interphase Fluorescence In Situ Hybridization

F. Jiang, F. Cabanillas, L. Medeiros, 2002 .

Coexpression of CD40 and CD40 ligand in B‐cell lymphoma cells

K. Kliche, M. Andreeff, F. Cabanillas, 1998, British journal of haematology.

Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1/2 clinical trial.

P. Mclaughlin, F. Cabanillas, K. Young, 2012, The Lancet. Oncology.

Report of the first workshop on prognostic factors in large-cell lymphomas.

J. Armitage, B. Coiffier, M. Shipp, 1991, Annals of oncology : official journal of the European Society for Medical Oncology.

Improvement of overall and failure-free survival in stage IV follicular lymphoma: 25 years of treatment experience at The University of Texas M.D. Anderson Cancer Center.

G. Ayers, S. Verstovsek, P. Mclaughlin, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prognostic significance of baseline peripheral absolute neutrophil, monocyte and serum β2‐microglobulin level in patients with diffuse large b‐cell lymphoma: a new prognostic model

Michael L. Wang, Y. Oki, P. Mclaughlin, 2016, British journal of haematology.

Non-Hodgkin's lymphoma: the old and the new.

F. Cabanillas, 2011, Clinical lymphoma, myeloma & leukemia.

Combined modality therapy for cutaneous T-cell lymphoma.

R. Kurzrock, S. Tucker, F. Cabanillas, 1996, Journal of the American Academy of Dermatology.

Phase II study of bortezomib in combination with rituximab, cyclophosphamide and prednisone with or without doxorubicin followed by rituximab maintenance in patients with relapsed or refractory follicular lymphoma

R. Neuwirth, D. Esseltine, F. Cabanillas, 2014, British journal of haematology.

Front-line management of diffuse large B cell lymphoma

F. Cabanillas, 2010, Current opinion in oncology.

Hyper-CVAD and high-dose methotrexate/cytarabine followed by stem-cell transplantation: an active regimen for aggressive mantle-cell lymphoma.

H. Kantarjian, F. Cabanillas, A. Younes, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Untreated Aggressive Mantle Cell Lymphoma: Results with Intensive Chemotherapy without Stem Cell Transplant in Elderly Patients

H. Kantarjian, P. Mclaughlin, F. Cabanillas, 2000, Leukemia & lymphoma.

What constitutes a "cure" in lymphoma?

D. Moore, F. Cabanillas, 1993, Leukemia & lymphoma.

The gallium scan predicts relapse in patients with Hodgkin's disease treated with combined modality therapy.

D. Podoloff, F. Cabanillas, F. Hagemeister, 1994, Annals of Oncology.

Mantle-cell lymphoma.

F. Cabanillas, J. Romaguera, I. Barista, 2001, The Lancet. Oncology.

Allogeneic hematopoietic transplantation for mantle-cell lymphoma: molecular remissions and evidence of graft-versus-malignancy.

H. Kantarjian, F. Cabanillas, M. Albitar, 1999, Annals of oncology : official journal of the European Society for Medical Oncology.

Report o f a n I nternational W orkshop t o S tandardize Response C riteria f or N on-Hodgkin's L ymphomas

J. Armitage, J. Vose, A. Hagenbeek, 1999 .

Treatment of patients with lymphomas of the uterus or cervix with combination chemotherapy and radiation therapy

L. Fuller, J. Cox, F. Cabanillas, 1995, Cancer.

Coincident renal cell carcinoma and nonHodgkin's lymphoma: the M. D. Anderson experience and review of the literature.

L. Pusztai, F. Cabanillas, J. Palmer, 1998, The Journal of urology.

High-dose melphalan and total body irradiation with bone marrow transplantation for refractory malignancies.

S. Jagannath, A. Zander, W. Velasquez, 1986, European journal of cancer & clinical oncology.

Experience with ifosfamide combinations in malignant lymphomas.

F. Cabanillas, 1989, Seminars in oncology.

Radiation therapy after a partial response to CHOP chemotherapy for aggressive lymphomas.

S. Tucker, J. Cox, F. Cabanillas, 2001, International journal of radiation oncology, biology, physics.

Antibody response to a two-dose influenza vaccine regimen in adult lymphoma patients on chemotherapy

R. Couch, L. Elting, F. Cabanillas, 1993, European Journal of Clinical Microbiology and Infectious Diseases.

Successful Use of Bortezomib-Lenalidomide Combination as Treatment for a Patient With Plasmablastic Lymphoma.

F. Cabanillas, C. Castillo, A. Cruz-Chacón, 2018, Clinical lymphoma, myeloma & leukemia.

Prognostic factors with high-dose melphalan for refractory multiple myeloma.

B. Barlogie, B. Cheson, F. Cabanillas, 1988, Blood.

Primary therapy of Waldenström's macroglobulinemia with 2-chlorodeoxyadenosine.

E. Estey, M. Dimopoulos, H. Kantarjian, 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Impact of high-dose chemotherapy on peripheral T-cell lymphomas.

M. Munsell, F. Cabanillas, B. Andersson, 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

CLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS ASHAP: A Regimen for Cytoreduction of Refractory or Recurrent Hodgkin's Disease

P. Mclaughlin, F. Cabanillas, B. Andersson, 2016 .

ASHAP: a regimen for cytoreduction of refractory or recurrent Hodgkin's disease.

P. Mclaughlin, F. Cabanillas, B. Andersson, 1999, Blood.

A phase II trial of oral etoposide with mitoxantrone and ifosfamide/mesna consolidated with intravenous etoposide, methylprednisolone, high-dose arabinoside, and cisplatin as salvage therapy for relapsing and/or refractory lymphomas

P. Mclaughlin, F. Cabanillas, A. Younes, 1994, Investigational New Drugs.

Advances in Lymphoma Research

F. Cabanillas, M. Rodriguez, 1996, Cancer Treatment and Research.

Salvage central lymphatic irradiation in follicular lymphomas following failure of chemotherapy: a feasibility study.

S. Tucker, J. Cox, F. Cabanillas, 1999, International journal of radiation oncology, biology, physics.

Long-term results favor allogeneic over autologous hematopoietic stem cell transplantation in patients with refractory or recurrent indolent non-Hodgkin's lymphoma.

P. Mclaughlin, F. Cabanillas, F. Cabanillas, 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

Impact o f H igh-Dose C hemotherapy o n P eripheral T -Cell Lymphomas

M. Munsell, F. Cabanillas, B. Andersson, 2001 .

Rituximab, Fludarabine, Mitoxantrone, and Dexamethasone (R-FND) for Relapsed Indolent Lymphomas (RIL).

P. Mclaughlin, F. Cabanillas, N. Dang, 2005 .

P. Mclaughlin, F. Cabanillas, G. Rassidakis, 2002, Seminars in oncology.

Paclitaxel (Taxol) for the treatment of lymphoma.

L. North, F. Cabanillas, A. Younes, 1997, Annals of oncology : official journal of the European Society for Medical Oncology.

Variations in Chemotherapy and Radiation Therapy in a Large Nationwide and Community-Based Cohort of Elderly Patients With Non-Hodgkin Lymphoma

Xianglin L. Du, S. Fang, F. Cabanillas, 2007, American journal of clinical oncology.

European Organization for Research and Treatment of Cancer and Groupe d'Etude des Lymphomes de l'Adulte very favorable and favorable, lymphocyte‐predominant Hodgkin disease

J. Cox, F. Cabanillas, A. Younes, 2002, Cancer.

Rituximab plus hyper‐CVAD alternating with MTX/Ara‐C in patients with newly diagnosed mantle cell lymphoma: 15‐year follow‐up of a phase II study from the MD Anderson Cancer Center

Michael L. Wang, H. Kantarjian, P. Mclaughlin, 2016, British journal of haematology.

Radiotherapy Alone for Lymphocyte‐Predominant Hodgkin's Disease

J. Cox, F. Cabanillas, A. Younes, 2002, Cancer journal.

Ifosfamide combinations in lymphoma.

F. Cabanillas, 1990, Seminars in oncology.

Frequency of gastrointestinal involvement and its clinical significance in mantle cell lymphoma

P. Mclaughlin, F. Cabanillas, L. Medeiros, 2003, Cancer.

Primary Effusion Lymphoma in an Hiv-Negative Patient with No Serologic Evidence of Kaposi's Sarcoma Virus

F. Cabanillas, J. Said, R. Katz, 2001, Leukemia & lymphoma.

Studies with ifosfamide in patients with malignant lymphoma.

F. Cabanillas, E. Freireich, V. Rodriguez, 1982, Seminars in oncology.

Establishment and characterization of human B-cell lymphoma cell lines using B-cell growth factor.

F. Cabanillas, A. Goodacre, S. Mehta, 1990, Blood.

Mantle Cell Lymphoma with t(11;22) (q13;q11.2) an indolent clinical variant?

F. Cabanillas, A. Cruz-Chacón, William D Marrero, 2018, Leukemia & lymphoma.

Intermediate‐grade lymphomas treated with cyclophosphamide‐doxorubicin‐vincristine‐prednisone‐bleomycin alternated with cyclophosphamide‐methotrexate‐etoposide‐dexamethasone. Application of prognostic models to data analysis

S. Tucker, W. Velasquez, L. Fuller, 1994, Cancer.

Evaluation of the MD Anderson tumor score for diffuse large B‐cell lymphoma in the rituximab era

Juan F. García, A. López-Guillermo, A. Salar, 2019, European journal of haematology.

An elevated serum beta‐2‐microglobulin level is an adverse prognostic factor for overall survival in patients with early‐stage Hodgkin disease

S. Tucker, J. Cox, F. Cabanillas, 2002, Cancer.

Results of Upfront Therapy for Marginal Zone Lymphoma

F. Cabanillas, M. Tírado-Gómez, D. Hallman, 2017, Clinical lymphoma, myeloma & leukemia.

Phase I study of maytansine using a 3-day schedule.

F. Cabanillas, E. Freireich, M. Burgess, 1978, Cancer treatment reports.

Use of the international prognostic index and the tumor score to detect poor-risk patients with primary mediastinal large B-cell lymphoma: a study of 37 previously untreated patients.

F. Cabanillas, A. Sarris, F. Hagemeister, 1998, Leukemia & lymphoma.

Primary mediastinal large cell lymphoma is characterized by an inverted pattern of large tumoral mass and low beta 2 microglobulin levels in serum and frequently elevated levels of serum lactate dehydrogenase.

F. Cabanillas, F. Cabanillas, R. Luthra, 1994, Annals of oncology : official journal of the European Society for Medical Oncology.

A 10-year update of CHOP-Bleo in the treatment of diffuse large-cell lymphoma.

F. Cabanillas, E. Freireich, R. Lee, 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Effects of intensive induction chemotherapy for extensive-disease small cell bronchogenic carcinoma in protected environment-prophylactic antibiotic units.

F. Cabanillas, M. Keating, G. Bodey, 1984, The American journal of medicine.

Decreased expression of the deleted in colorectal carcinoma gene in non-Hodgkin's lymphoma.

S. Zhao, M. Andreeff, F. Cabanillas, 1995, Blood.

Check this checkpoint inhibitor in lymphoma.

F. Cabanillas, Noridza Rivera, 2017, Blood.

Ifosfamide, methotrexate, and vincristine (IMV) combination chemotherapy as secondary treatment for patients with malignant lymphoma.

F. Cabanillas, V. Rodriguez, G. Bodey, 1980, Cancer treatment reports.

Results of a Phase II Study of 506U78 (Nelarabine) in Refractory Indolent B-Cell or Peripheral T-Cell Lymphoma.

A. Bleyer, F. Cabanillas, A. Sarris, 2005 .

A randomized trial of CHOP chemotherapy with or without melatonin in patients with favorable prognosis large B-cell lymphoma.

F. Cabanillas, N. Dang, E. Grimm, 2004, Journal of Clinical Oncology.

A proposed approach for the selection of the proper surgical therapy to obtain an adequate margin of resection in locally advanced ultra-low rectal cancer after modern preoperative CRX management.

F. Cabanillas, G. Isenberg, I. Echenique, 2009, Boletin de la Asociacion Medica de Puerto Rico.

Is there an increased rate of additional malignancies in patients with mantle cell lymphoma?

F. Cabanillas, S. Strom, L. Medeiros, 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

T-Cell Rich B-Cell Lymphoma: Authors' Response

F. Cabanillas, W. Pugh, J. McBride, 1997 .

Fludarabine phosphate: a new active agent in hematologic malignancies.

H. Kantarjian, F. Cabanillas, W. Plunkett, 1994, Seminars in hematology.

Phase I study of fludarabine and paclitaxel for the treatment of low-grade non-Hodgkin's lymphoma.

P. Mclaughlin, L. North, F. Cabanillas, 1997, Leukemia & lymphoma.

Clinical relevance of Hodgkin’s-like anaplastic large cell lymphoma

F. Cabanillas, 1999 .

16-year experience at M. D. Anderson Cancer Center with primary Ki-1 (CD30) antigen expression and anaplastic morphology in adult patients with diffuse large cell lymphoma.

F. Cabanillas, J. García-Foncillas, J. Romaguera, 1995, Leukemia & lymphoma.

Study of the natural history of immunoblastic lymphadenopathy and atypical immunoproliferative disorders.

H. Libshitz, F. Cabanillas, B. Osborne, 1983, Cancer investigation.

Purine nucleoside analogs in indolent non-Hodgkin's lymphoma.

F. Cabanillas, 2000, Oncology.

Abstract P3-14-17: Results of a novel neoadjuvant chemotherapy (NAC) for breast cancer

F. Cabanillas, M. Echenique, Karen J. Santiago, 2013 .

Hyper-CVAD P rogram i n B urkitt's-Type A dult A cute Lymphoblastic L eukemia

H. Kantarjian, J. Cortes, F. Cabanillas, 1999 .

Rituximab Plus Hypercvad (R-HCVAD) Alternating with Rituximab Plus High-Dose Methotrexate-Cytarabine (R-M/A) in Untreated Mantle Cell Lymphoma (MCL): Prolonged Follow-Up Confirms High Rates of Failure-Free Survival (FFS) and Overall Survival (OS).

P. Mclaughlin, F. Cabanillas, L. Medeiros, 2004 .

Multicentric Castleman's disease.

J. Herrada, F. Cabanillas, 1995, American journal of clinical oncology.

Long‐term results of treatment of patients with follicular lymphomas

F. Cabanillas, S. Kalter, L. Holmes, 1987, Hematological oncology.

Rituximab (R) + Hypercvad Alternating with R-Methotrexate/Cytarabine after 9 Years: Continued High Rate of Failure-Free Survival in Untreated Mantle Cell Lymphoma (MCL)

Michael L. Wang, H. Kantarjian, P. Mclaughlin, 2008 .

Bortezomib In Combination with Rituximab, Cyclophosphamide, and Prednisone with or without Doxorubicin Followed by Rituximab Maintenance In Patients with Relapsed or Refractory Follicular Lymphoma: Results of a Phase 2 Study.

R. Neuwirth, F. Cabanillas, O. O’Connor, 2010 .

Thalidomide for patients with recurrent lymphoma

P. Mclaughlin, F. Cabanillas, M. Albitar, 2004, Cancer.

Unusual presentations of non-Hodgkin’s lymphomas in homosexual males

B. Barlogie, W. Velasquez, E. Hersh, 1985 .

Mucosa-associated lymphoid tissue lymphoma with initial supradiaphragmatic presentation: natural history and patterns of disease progression.

Z. Liao, P. Mclaughlin, J. Manning, 2000, International journal of radiation oncology, biology, physics.

Malt (mucosa associated lymphoid tissue) lymphoma with supradiaphragmatic presentation: Natural history and patterns of failure

Z. Liao, P. Mclaughlin, J. Manning, 1998 .

Outcomes of high-dose unilateral kidney irradiation in patients with gastric lymphoma.

L. North, J. Cox, F. Cabanillas, 1998, International journal of radiation oncology, biology, physics.

Treatment of early stages of Hodgkin's disease with novantrone, vincristine, vinblastine, prednisone, and radiotherapy.

L. Fuller, P. Mclaughlin, F. Cabanillas, 1994, Seminars in hematology.

Stage I Hodgkin disease: radiation therapy and chemotherapy at the University of Texas M. D. Anderson Cancer Center, 1996-1997.

S. Tucker, L. Fuller, J. Cox, 1998, Radiology.

Preliminary experience with paclitaxel for the treatment of relapsed and refractory Hodgkin's disease.

P. Mclaughlin, F. Cabanillas, A. Younes, 1996, Annals of oncology : official journal of the European Society for Medical Oncology.

POEMS Syndrome: A Rare Disease With A Challenging Diagnosis.

F. Cabanillas, Glorilee Delgado Flores, América Robles Cartagena, 2015, Boletin de la Asociacion Medica de Puerto Rico.

Effective salvage therapy for lymphoma with cisplatin in combination with high-dose Ara-C and dexamethasone (DHAP).

S. Jagannath, S. Tucker, W. Velasquez, 1988, Blood.

Clinical correlates of elevated serum levels of interleukin 6 in patients with untreated Hodgkin's disease.

R. Kurzrock, F. Cabanillas, F. Cabanillas, 1997, The American journal of medicine.

Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.

R. Levy, M. Czuczman, A. Ho, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Testicular lymphoma: late relapses and poor outcome despite doxorubicin-based therapy.

J. Cox, F. Cabanillas, A. Younes, 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

High-dose therapy and autologous bone marrow transplantation after failure of conventional chemotherapy in adults with intermediate-grade or high-grade non-Hodgkin's lymphoma.

J. Armitage, S. Jagannath, P. Biron, 1987, The New England journal of medicine.

Outcomes of high-dose unilateral kidney irradiation in patients with gastric lymphoma.

L. North, J. Cox, F. Cabanillas, 1998, International journal of radiation oncology, biology, physics.

Follicular large cell lymphoma: Long-term follow-up of 62 patients

P. Mclaughlin, F. Cabanillas, L. Fayad, 2000 .

Recent advances in the management of mantle cell lymphoma

F. Cabanillas, N. Rivera-Rodríguez, 2013, Current opinion in oncology.

Hodgkin's disease: study of treatment intensities and incidences of second malignancies.

S. Zimmerman, M. Munsell, W. Velasquez, 1993, Annals of oncology : official journal of the European Society for Medical Oncology.

Follicular large cell lymphoma: analysis and prognostic factors in 62 patients.

H. Kantarjian, L. Fuller, P. Mclaughlin, 1984, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

P. Mclaughlin, F. Cabanillas, A. Tsimberidou, 2002, Seminars in oncology.

Non-Hodgkin's lymphomas: a review of the M.D. Anderson experience.

F. Cabanillas, 1992, Seminars in Oncology.

Hodgkin's disease: correlation of clinical characteristics with probabilities for negative lymphangiogram vs. negative laparotomy findings in patients with Stage I supradiaphragmatic presentations vs. those in patients with Stage II.

L. Fuller, P. Mclaughlin, L. North, 1998, International journal of radiation oncology, biology, physics.

Single-Arm, Open-Label Phase 2 Trial of Preemptive Methylprednisolone to Avert Progression to Respiratory Failure in High-Risk Patients with COVID-19

F. Cabanillas, J. Bertrán-Pasarell, Y. Hernandez-Silva, 2021, medRxiv.

Front-line management of diffuse large B cell lymphoma

F. Cabanillas, 2010, Current opinion in oncology.

Marginal zone lymphomas

P. Iyengar, P. Mclaughlin, F. Cabanillas, 2010, Cancer.

Rituximab plus hyper‐CVAD alternating with MTX/Ara‐C in patients with newly diagnosed mantle cell lymphoma: 15‐year follow‐up of a phase II study from the MD Anderson Cancer Center

Michael L. Wang, H. Kantarjian, P. Mclaughlin, 2016, British journal of haematology.

R. Neuwirth, D. Esseltine, F. Cabanillas, 2014, British journal of haematology.

Blastoid Mantle Cell Lymphoma (MCL): 5-yr Failure-Free Survival (FFS) Rate of 50%, without Failures after 2.5 Years Following Treatment with Rituximab (R)-HyperCVAD Alternating with R-Methotrexate/Cytarabine (M/A).

H. Kantarjian, P. Mclaughlin, F. Cabanillas, 2006 .

Gastric MALT Lymphoma with Biclonal Gammopathy and Bone Marrow Involvement Mimicking Multiple Myeloma.

F. Cabanillas, D. Conde-Sterling, E. Sobrino-Najul, 2020, Puerto Rico health sciences journal.

New initiatives with fludarabine monophosphate in hematologic malignancies.

V. Grégoire, H. Kantarjian, P. Mclaughlin, 1993, Seminars in oncology.

NOVP: a novel chemotherapeutic regimen with minimal toxicity for treatment of Hodgkin's disease.

W. Velasquez, F. Cabanillas, M. Meistrich, 1990, Seminars in oncology.

A Phase I/II Study of Lenalidomide in Combination with Rituximab in Relapsed/Refractory Mantle Cell Lymphoma.

P. Mclaughlin, F. Cabanillas, A. Younes, 2009 .

The Addition of Rituximab to CHOP Chemotherapy Improves Response Rate, Failure-Free Survival and Overall Survival for Follicular Grade 3 Lymphoma Compared to CHOP Alone

P. Mclaughlin, F. Cabanillas, M. Overman, 2007 .

Prospective trial of targeted radioimmunotherapy with Y-90 ibritumomab tiuxetan (Zevalin) for front-line treatment of early-stage extranodal indolent ocular adnexal lymphoma.

B. Esmaeli, P. Mclaughlin, F. Cabanillas, 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

non- Hodgkin's lymphoma Decreased expression of the deleted in colorectal carcinoma gene in

M. Andreeff, F. Cabanillas, A. Younes, 2012 .